These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11450615)

  • 1. [Cytokine and anti-cytokine therapy in chronic inflammatory bowel diseases].
    Wittig BM; Zeitz M
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S52-8. PubMed ID: 11450615
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-cytokine therapy in inflammatory joint diseases].
    Ehrenfeld M; Langevitz P; Shoenfeld Y
    Harefuah; 1999 Aug; 137(3-4):120-4. PubMed ID: 10959300
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

  • 7. [Chronic inflammatory bowel disease--pathogenic concepts and therapeutic perspectives].
    Madsen JR
    Ugeskr Laeger; 2000 Mar; 162(10):1361-6. PubMed ID: 10745672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D; Sémana G; Gosselin M; Bretagne MG
    Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone in inflammatory bowel disease.
    De Pascalis B; Bianchi A; Satta MA; Lupascu A; Mentella MC; Leo D; Fiore F; Fedeli P; Pontecorvi A; Pola P; Melina D; Gasbarrini A; De Marinis L; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2006; 10(1):13-6. PubMed ID: 16494105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy.
    van Hogezand RA; Verspaget HW
    Scand J Gastroenterol Suppl; 1997; 223():105-7. PubMed ID: 9200315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases].
    Allez M
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):467-77. PubMed ID: 18448294
    [No Abstract]   [Full Text] [Related]  

  • 12. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
    [No Abstract]   [Full Text] [Related]  

  • 13. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ
    Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine-based therapies for Crohn's disease--new paradigms.
    Cominelli F
    N Engl J Med; 2004 Nov; 351(20):2045-8. PubMed ID: 15537904
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
    Danese S
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of inflammatory bowel diseases].
    Silvennoinen J; Niemelä S
    Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
    [No Abstract]   [Full Text] [Related]  

  • 18. [Practice guidelines in gastroenterology. Use of anti-TNF agents in inflammatory bowel disease. European guide 2001-2003].
    Rom J Gastroenterol; 2002 Mar; 11(1):68-71. PubMed ID: 12219731
    [No Abstract]   [Full Text] [Related]  

  • 19. New cytokine therapeutics for inflammatory bowel disease.
    Stokkers PC; Hommes DW
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.
    Magro F
    BioDrugs; 2010 Dec; 24 Suppl 1():1-2. PubMed ID: 21175227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.